{
    "2018-10-04": [
        [
            {
                "time": "2018-10-01",
                "original_text": "Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam",
                "features": {
                    "keywords": [
                        "Roche",
                        "Encouraging Data",
                        "SMA Drug",
                        "Risdiplam"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-02",
                "original_text": "Novartis ADR’s Performance and Revenue Estimates for Q3 2018",
                "features": {
                    "keywords": [
                        "Novartis",
                        "ADR",
                        "Performance",
                        "Revenue Estimates",
                        "Q3 2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-03",
                "original_text": "GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "ADR",
                        "Performance",
                        "Revenues",
                        "Q3 2018"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-04",
                "original_text": "Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US",
                "features": {
                    "keywords": [
                        "Moody's",
                        "Biosimilars",
                        "growing challenge",
                        "biotech drugs",
                        "European market",
                        "US"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}